Skip to Content
Merck
All Photos(1)

Key Documents

More Documents

361275

Sigma-Aldrich

3′-Deoxy-3′-fluorothymidine

97%

Synonym(s):

3′-Fluoro-2′,3′-dideoxythymidine, 3′-Fluorodeoxythymidine

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C10H13FN2O4
CAS Number:
25526-93-6
Molecular Weight:
244.22
MDL number:
MFCD00056058
UNSPSC Code:
12352200
PubChem Substance ID:
24862180
NACRES:
NA.22

Quality Level

100

Assay

97%

form

solid

mp

176-178 °C (lit.)

storage temp.

2-8°C

SMILES string

CC1=CN([C@H]2C[C@H](F)[C@@H](CO)O2)C(=O)NC1=O

InChI

1S/C10H13FN2O4/c1-5-3-13(10(16)12-9(5)15)8-2-6(11)7(4-14)17-8/h3,6-8,14H,2,4H2,1H3,(H,12,15,16)/t6-,7+,8+/m0/s1

InChI key

UXCAQJAQSWSNPQ-XLPZGREQSA-N

Gene Information

human ... TK2(7084)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Promising antiviral agent possessing activity similar to other 3′-deoxy-3′-substituted thymidines.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Eliot T McKinley et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(3), 424-430 (2013-01-24)
Selective inhibition of oncogenic targets and associated signaling pathways forms the basis of personalized cancer medicine. The clinical success of (V600E)BRAF inhibition in melanoma, coupled with the emergence of acquired resistance, underscores the importance of rigorously validating quantitative biomarkers of
Nicolas Graf et al.
European journal of nuclear medicine and molecular imaging, 40(1), 34-43 (2012-10-12)
Positron emission tomography (PET) with the thymidine analogue [(18)F]fluorothymidine ([(18)F]FLT) has been shown to detect early response to chemotherapy in high-grade lymphoma. In this preclinical in vitro and in vivo study we compared [(18)F]FLT to the glucose analogue [(18)F]fluorodeoxyglucose ([(18)F]FDG)
Tyler J Bradshaw et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(11), 1931-1937 (2013-09-18)
Intratumor heterogeneity in biologic properties and in relationships between various phenotypes may present a challenge for biologically targeted therapies. Understanding the relationships between different phenotypes in individual tumor types could help inform treatment selection. The goal of this study was
A Van Aerschot et al.
Journal of medicinal chemistry, 32(8), 1743-1749 (1989-08-01)
A series of 2'- and 3'-fluorinated 2',3'-dideoxynucleosides and 3'-azido-2',3'-dideoxynucleosides were synthesized and evaluated for their inhibitory activity against human immunodeficiency virus-1 (HIV-1) replication in MT-4 cells. Neither conversion of 3'-fluoro- or 3'-azido-2',3'-dideoxyadenosine to the corresponding inosine derivatives nor 8-bromination of
Deniz Kahraman et al.
Clinical nuclear medicine, 37(11), 1058-1064 (2012-10-03)
The aim was to assess the value of tumor lesion glycolysis (TLG) and tumor lesion proliferation (TLP) determined by FDG and 3'-deoxy-3'-F-fluorothymidine (FLT) PET for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer (NSCLC) treated
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service